Results 181 to 190 of about 7,910 (224)

Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban

Vascular Pharmacology, 2016
Glycoprotein (GP) IIb/IIIa inhibitors block platelet aggregation, reducing thrombotic events in acute coronary syndrome. They are most often utilized in patients who likely have an intracoronary thrombus. Tirofiban, eptifibatide, and abciximab are the three GP IIb/IIIa inhibitors approved for use in the United States.
Marintha Short, Shawn King, Cassidy Harmon   +2 more
exaly   +4 more sources

Safety evaluation of tirofiban

Expert Opinion on Drug Safety, 2010
Heightened platelet activity is pivotal in the thrombosis underlying acute coronary syndrome (ACS). The glycoprotein IIb/IIIa inhibitor tirofiban is a powerful platelet inhibitor with demonstrated efficacy and safety across the spectrum of ACS. Despite tirofiban's impact on the platelet compared with placebo, only an excess in minor and importantly not
Marco Valgimigli, Matteo Tebaldi
openaire   +3 more sources

Risedronate Sodium and Tirofiban Hydrochloride [PDF]

Hospital Pharmacy, 1999
Each month, subscribers to The Formulary® receive print and electronic versions of at least six monographs reviewing new drug entities or related drugs within a category. Some reviews take a second look at currently available drugs, whereas other preliminarily evaluate agents about to be released—just in time for use with your Pharmacy and ...
Danial E. Baker, Terri Levien
openaire   +1 more source

Tirofiban for myocardial infarction

Expert Opinion on Pharmacotherapy, 2010
Inhibition of platelet aggregation plays a key role in treatment of coronary artery disease.Studies on the effects of tirofiban in patients with either ST elevation or non-ST elevation myocardial infarction are reviewed.Tirofiban is a small-molecule glycoprotein IIb/IIIa receptor inhibitor. If discontinued, the action of tirofiban is faster reversed as
Harry Suryapranata, Arnoud W J van 't Hof, Jan Paul Ottervanger, Yahya B. Juwana   +3 more
openaire   +2 more sources

Tirofiban for the treatment of ischaemic stroke

Expert Opinion on Pharmacotherapy, 2005
Tirofiban is one of three glycoprotein IIb/IIIa receptor antagonists approved by the US FDA, beside abciximab and eptifibatide. The approval of tirofiban covers conservative treatment of myocardial infarction and unstable angina, as well as percutaneous coronary intervention, for which treatment with tirofiban is recommended in moderate-to-high-risk ...
Michael Daffertshofer, Michael G. Hennerici, Simone Bukow   +2 more
openaire   +3 more sources

Tirofiban-associated acute thrombocytopenia

Acta Cardiologica, 2006
Randomized clinical trials of glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention have shown significant clinical efficacy and safety in reducing the morbidity and mortality. In Turkey, only tirofiban is available. Tirofiban is a safe and effective agent in combination with heparin and aspirin in the setting of an acute coronary ...
Tuhta, Aylin G., Yesildag, Osman, Koprulu, Dyyar   +2 more
openaire   +4 more sources

Tirofiban in acute coronary syndromes

Expert Review of Cardiovascular Therapy, 2005
Acute coronary syndromes represent a major health problem in terms of incidence and mortality. Intracoronary platelet-rich thrombi may develop in response to plaque rupture, and are involved in the pathogenesis of all acute coronary syndromes. The glycoprotein IIb/IIIa receptor, a platelet surface integrin, plays a key role in platelet aggregation once
Alberto Menozzi, Diego Ardissino, Piera Angelica Merlini   +2 more
openaire   +3 more sources

Safety and efficacy of Tirofiban in STEMI-patients

International Journal of Cardiology, 2019
Tirofiban is recommended as bail out therapy in patients with ST-elevation myocardial infarction (STEMI). However, evidence regarding safety and efficacy of tirofiban is unclear. Tirofiban has been shown to improve ST-resolution, to decrease infarct size (IS) and to reduce incidence of major adverse cardiac and cerebrovascular events (MACCE).
Dannenberg, Lisa, Wolff, Georg, Naguib, David, Pöhl, Martin, Zako, Saif, Helten, Carolin, Mourikis, Philipp, Levkau, Bodo, Hohlfeld, Thomas, Zeus, Tobias, Kelm, Malte, Schulze, Volker, Polzin, Amin   +12 more
openaire   +3 more sources

In Vitro and In Vivo Studies on the Metabolism of Tirofiban

Drug Metabolism and Disposition, 1999
Tirofiban hydrochloride [L-tyrosine-N-(butylsulfonyl)-O-[4-(4-piperidinebutyl)] monohydrochloride, is a potent and specific fibrinogen receptor antagonist. Radiolabeled tirofiban was synthesized with either (3)H-label incorporated into the phenyl ring of the tyrosinyl residue or (14)C-label in the butane sulfonyl moiety.
S, Vickers, A D, Theoharides, B, Arison, S K, Balani, D, Cui, C A, Duncan, J D, Ellis, L M, Gorham, S L, Polsky, T, Prueksaritanont, H G, Ramjit, D E, Slaughter, K P, Vyas   +12 more
openaire   +2 more sources

Current strategies with high-dose tirofiban

Expert Opinion on Drug Metabolism & Toxicology, 2007
The glycoprotein (GP) IIb/IIIa receptor is a platelet-specific adhesion receptor that mediates the formation of platelet aggregates. Pharmacologic blockade of the receptor is associated with a reduction in major cardiovascular adverse events after percutaneous coronary interventions and in the setting of acute coronary syndromes.
Marco Roffi, Debabrata Mukherjee
openaire   +3 more sources